KR102378298B1 - Ｐｄ-1/ｐｄｌ-1 표적화 약물에 대한 반응의 평가 방법 - Google Patents

Ｐｄ-1/ｐｄｌ-1 표적화 약물에 대한 반응의 평가 방법 Download PDF

Info

Publication number
KR102378298B1
KR102378298B1 KR1020187020429A KR20187020429A KR102378298B1 KR 102378298 B1 KR102378298 B1 KR 102378298B1 KR 1020187020429 A KR1020187020429 A KR 1020187020429A KR 20187020429 A KR20187020429 A KR 20187020429A KR 102378298 B1 KR102378298 B1 KR 102378298B1
Authority
KR
South Korea
Prior art keywords
vhl
cancer
targeting
patient
loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187020429A
Other languages
English (en)
Korean (ko)
Other versions
KR20180115262A (ko
Inventor
살렘 추아입
요스라 메사이
무함마드 자임 노만
Original Assignee
인스티튜트 구스타브 루시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인스티튜트 구스타브 루시 filed Critical 인스티튜트 구스타브 루시
Publication of KR20180115262A publication Critical patent/KR20180115262A/ko
Application granted granted Critical
Publication of KR102378298B1 publication Critical patent/KR102378298B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G01N33/57484—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/57438—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187020429A 2015-12-18 2016-12-16 Ｐｄ-1/ｐｄｌ-1 표적화 약물에 대한 반응의 평가 방법 Active KR102378298B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15307050 2015-12-18
EP15307050.3 2015-12-18
PCT/EP2016/081485 WO2017103147A1 (en) 2015-12-18 2016-12-16 Method for assessing the response to pd-1/pdl-1 targeting drugs

Publications (2)

Publication Number Publication Date
KR20180115262A KR20180115262A (ko) 2018-10-22
KR102378298B1 true KR102378298B1 (ko) 2022-03-23

Family

ID=55129471

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187020429A Active KR102378298B1 (ko) 2015-12-18 2016-12-16 Ｐｄ-1/ｐｄｌ-1 표적화 약물에 대한 반응의 평가 방법

Country Status (5)

Country Link
US (1) US11137404B2 (https=)
JP (1) JP6762363B2 (https=)
KR (1) KR102378298B1 (https=)
IL (1) IL260024B (https=)
WO (1) WO2017103147A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101980003B1 (ko) * 2017-09-14 2019-05-17 건국대학교 글로컬산학협력단 면역체크포인트의 발현을 억제하기 위한 물질을 포함하는 나노입자 전달체
KR102216725B1 (ko) * 2017-12-29 2021-02-17 연세대학교 산학협력단 면역 항암 요법에 대한 치료 반응 예측 방법
WO2019159825A1 (ja) * 2018-02-14 2019-08-22 国立大学法人名古屋大学 抗ｐｄ－１抗体／抗ｐｄ－ｌ１抗体療法の効果を予測するバイオマーカー
GB201805876D0 (en) * 2018-04-09 2018-05-23 Francis Crick Institute Ltd Method
JP2022533012A (ja) * 2019-04-30 2022-07-21 エックスセル・バイオサイエンシズ・インコーポレイテッド 細胞表現型を調節するための系および方法
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
KR20230125672A (ko) * 2022-02-21 2023-08-29 사회복지법인 삼성생명공익재단 암 환자에 대한 면역관문억제제의 반응성 예측용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518826A (ja) 2012-05-15 2015-07-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔ Ｐｄ−１／ｐｄ−ｌ１シグナル伝達を破壊することによる癌免疫療法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518826A (ja) 2012-05-15 2015-07-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔ Ｐｄ−１／ｐｄ−ｌ１シグナル伝達を破壊することによる癌免疫療法

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
B Beuselinck et al, Clinical Cancer Research (2015.01.12.), vol 21, no 6, pp 1329-1339.
Messai Yosra et al, European Urology (2015.12.23.), vol 70, no 4, pp 623-632.
Noman Muhammad Zaeem et al, Cancer Microenvironment (2014.10.22.), vol 7, no 3, pp 153-160.
P D Sutphin et al, Cancer Research (2007.06.15.), pp 5896-5905.
Scott Tykodi et al, Oncotargets and Therapy (2014.07.01.), pp 1349.
Solene Florence Kammerer Jacquet et al, International Journal of Cancer (2016.09.13.), vol 140, no 1, pp 142-148.
Susan A J Vaziri et al, Frontiers in Oncology (2012.05.28.), vol 2, XP055347667.
Y Messai et al, Cancer Research (2014.10.08.), vol 74, no 23, pp 6820-6832.
Yosra Messai et al, Oncoimmunology (2015.03.06.), vol 4, no 2, pp e985951.
Zitvogel L et al, Oncoimmunology (2012.11.01.), vol 1, no 8, pp 1223-1225.

Also Published As

Publication number Publication date
JP6762363B2 (ja) 2020-09-30
US11137404B2 (en) 2021-10-05
KR20180115262A (ko) 2018-10-22
WO2017103147A1 (en) 2017-06-22
IL260024A (en) 2018-07-31
IL260024B (en) 2021-07-29
JP2019500870A (ja) 2019-01-17
US20180364241A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
KR102378298B1 (ko) Ｐｄ-1/ｐｄｌ-1 표적화 약물에 대한 반응의 평가 방법
Schuster et al. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
Brueckl et al. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
Dyck et al. Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function
Lopez-Bujanda et al. Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression
Reifenberger et al. Advances in the molecular genetics of gliomas—implications for classification and therapy
Arts et al. PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis
Teo et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers
Colle et al. Immunotherapy and patients treated for cancer with microsatellite instability
Wang et al. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells
KR20190015408A (ko) 종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
PT1994410E (pt) Métodos e estojos para detecção precoce de cancro ou de predisposição a este
Tabatabai et al. Clinical implications of molecular neuropathology and biomarkers for malignant glioma
JP2018516870A (ja) ３つの完全ヒトモノクローナル抗ｅｇｆｒ抗体の組み合わせを用いて上皮成長因子受容体（ｅｇｆｒ）の細胞外ドメインに変異を有する患者を治療する方法
JP2019529437A (ja) 抗ｐｄ−ｌ１抗体単独療法に対する固形腫瘍の奏効性を特徴付けるための組成物および方法
Derer et al. Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression
Rogers et al. Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities
Larsen et al. EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib
Krawczyk et al. Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer
EP3391054B1 (en) Method for assessing the response to pd-1/pdl-1 targeting drugs
WO2022112198A1 (en) Method to select the optimal immune checkpoint therapies
Deka et al. Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
CN121100126A (zh) 配体依赖性辅阻遏物（lcor）的突变体及其用途
EP4499875A1 (en) Biomarkers of il7r modulator activity
Cen et al. Biomarkers in oncology and nephrology

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
A302 Request for accelerated examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5